Harvey Capital Management Inc. Has $1.45 Million Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Harvey Capital Management Inc. grew its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 86.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 499,570 shares of the company's stock after purchasing an additional 232,180 shares during the period. Harvey Capital Management Inc. owned approximately 0.51% of Aquestive Therapeutics worth $1,449,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. acquired a new stake in Aquestive Therapeutics during the first quarter valued at $33,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aquestive Therapeutics in the fourth quarter worth $44,000. Two Sigma Advisers LP acquired a new position in Aquestive Therapeutics in the 4th quarter valued at $57,000. PKS Advisory Services LLC acquired a new position in Aquestive Therapeutics during the 4th quarter worth $63,000. Finally, Penbrook Management LLC bought a new stake in Aquestive Therapeutics during the first quarter valued at about $65,000. Hedge funds and other institutional investors own 32.45% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Oppenheimer started coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of "Buy" and an average target price of $10.14.

Aquestive Therapeutics Stock Down 0.5%

Shares of AQST stock traded down $0.02 during mid-day trading on Friday, reaching $4.01. The stock had a trading volume of 1,146,536 shares, compared to its average volume of 1,498,430. The firm has a market cap of $398.31 million, a PE ratio of -6.80 and a beta of 1.97. Aquestive Therapeutics, Inc. has a one year low of $2.12 and a one year high of $5.80. The firm's 50 day simple moving average is $3.08 and its 200 day simple moving average is $3.01.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The business had revenue of $8.72 million for the quarter, compared to analysts' expectations of $12.23 million. Sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.